• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans

Photo
- - - - -

NR treatment markedly improved mitochondrial respiration, cardiomyocyte survival, and contractile function in mice

nicotinamide riboside animal study cardiac function cardiomyocytes mitochondrial unfolded protein response uprmt mitochondrial function

  • This topic is locked This topic is locked
3 replies to this topic
⌛⇒ MITOMOUSE has been fully funded!

#1 Fredrik

  • Guest
  • 538 posts
  • 128
  • Location:Stockholm, Sweden
  • NO

Posted 09 April 2019 - 03:51 PM


From Chromadex press release and link to the full independent study that was published yesterday:

 

"...supplementation with the unique B3 vitamin nicotinamide riboside (NR, or Niagen®) helps maintain heart function in mice by stimulating a conserved cellular response called the “mitochondrial unfolded protein response” (UPRmt) that helps maintain mitochondrial function.

 

The study also presents preliminary human data to support future testing of NR in humans. Conducted by Principal Investigators Prof. Ajay M. Shah and Dr. Ioannis Smyrnias, Kings College London, the independent study results were published yesterday in the Journal of the American College of Cardiology (JACC).  This study follows clinical results from last year highlighting the potential for NR supplementation to improve cardiovascular health.

 

“NR supplementation is a new and exciting intervention that merits testing in the human treatment of heart failure and other cardiac conditions,” said Prof. Shah. “These study findings showing the potential of NR to activate UPRmt are extremely encouraging and merit further research into the potential for NR to impact human cardiac health.”

 

 

In several complementary experiments, the authors found that increasing NAD levels with NR stimulated the UPRmt in cells and mice. Additionally, NR helped improve mitochondrial function and maintained the heart’s ability to pump blood.

To begin to investigate whether these findings might translate to humans, the study authors collected heart tissue samples from people and found positive correlations between increased UPRmt activation and markers of healthy heart function. Human studies were performed under institutional ethical approval and with informed consent.

 

Published in the Journal of the American College of Cardiology

Volume 73, Issue 14, April 2019

DOI: 10.1016/j.jacc.2018.12.087

 

Cardioprotective Effect of the Mitochondrial Unfolded Protein Response During Chronic Pressure Overload
Ioannis Smyrnias, Stephen P. Gray, Darlington O. Okonko, Greta Sawyer, Anna Zoccarato, Norman Catibog, Begoña López, Arantxa González, Susana Ravassa, Javier Díez and Ajay M. Shah

 

"...this is the first study to identify activation of the UPRmt in response to diverse in vitro and in vivo stresses in the mammalian myocardium. We also show that pharmacological boosting of the UPRmt preserves mitochondrial function and cardiomyocyte viability under pathological stress conditions relevant to heart failure. Taken together, the results suggest that the targeting of the UPRmt merits further investigation as a therapeutic strategy for heart failure.

 

http://www.onlinejac...tent/73/14/1795


Edited by Fredrik, 09 April 2019 - 04:13 PM.

  • Informative x 2

#2 Harkijn

  • Member
  • 661 posts
  • 186
  • Location:Amsterdam
  • NO

Posted 09 April 2019 - 05:29 PM

And this one, also in mice, seems to point to very positive outcomes in lactation.

https://www.ncbi.nlm...pubmed/30797625



#3 Fredrik

  • Topic Starter
  • Guest
  • 538 posts
  • 128
  • Location:Stockholm, Sweden
  • NO

Posted 09 April 2019 - 08:36 PM

The editorial comment of the study:

 

Unfolding the Roles of Mitochondria as Therapeutic Targets for Heart Disease

 

https://sci-hub.tw/1...acc.2018.12.089



⌛⇒ MITOMOUSE has been fully funded!

#4 bluemoon

  • Guest
  • 742 posts
  • 90
  • Location:south side
  • NO

Posted 10 April 2019 - 12:10 PM

The  U of Washington NR trial with heart failure patients ends in June so a year before those results are published but Iowa State U's cardiovascular trial ended last December so results might be published by the end of this year:

 

"The purpose of this study is to determine the effects of Nicotinamide Riboside (NR) supplementation on metabolism and vascular function following high-fat meal. Differences between young (18-35) and older (60-75) adults will be determined."







Also tagged with one or more of these keywords: nicotinamide riboside, animal study, cardiac function, cardiomyocytes, mitochondrial unfolded protein response, uprmt, mitochondrial function

3 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users


    Bing (2)